Claim Missing Document
Check
Articles

Found 3 Documents
Search

Workshop dan Edukasi Pemanfaatan Herbal sebagai Upaya Peningkatan Kesehatan Keluarga pada Anggota PKK: Workshop and Education on Herbal Utilization to Enhance Family Health for PKK Members Ebtavanny, Tamara Gusti; Hariadini, Ayuk Lawuningtyas; Firdaus, Favian Rafif; Achmad, Anisyah; Amalia, Thia; Nabilah, Varna Amalia; Fauzan, Evan; Azis, Umar Abdul; Wibowo, Andriani Abigail
PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat Vol. 10 No. 4 (2025): PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/pengabdianmu.v10i4.8709

Abstract

The Family Welfare Empowerment (PKK) is a community group dedicated to fostering family and societal well-being, with health being one of its key focus areas. PKK members are pivotal in enhancing family immunity, particularly during heightened risk from bacterial, viral, and other infections. The community's preference for traditional medicine, which has been empirically proven to be safe and effective, such as *Andrographis paniculata* (sambiloto) and *Curcuma longa L.* (turmeric), serves as a viable solution for boosting family immunity. This program aimed to provide education and workshops to 50 PKK members in Kendalpayak Village through education sessions, pre-and post-tests, a herbal drink preparation workshop, and follow-up consultations. The education covered topics on the immune system, the definition and application of traditional medicine, and the rational use of herbal remedies. The program results revealed a significant improvement in participants' knowledge, with average pre-test scores of 81.71 rising to 93.90 in post-tests, reflecting a 12.19% increase. Furthermore, the proportion of participants with "Good" knowledge levels rose from 75.61% to 92.68%. The workshop successfully trained participants in practical herbal preparation by demonstrating the production of three types of immune-boosting herbal drinks, supported by educational materials that had obtained intellectual property rights. Participant satisfaction with the program was notably high, averaging 96.06%. These results demonstrate the program's tangible benefits in enhancing community knowledge and skills, potentially supporting family health and well-being in the future.
Cost-Effectiveness Analysis of The Antibiotic Ampicillin and Cefuroxime for Bronchopneumonia Patients Toddlers at Secondary Hospital in Surabaya Wardhani, Dewanti; Firdaus, Favian Rafif; Yunita, Nita; Abdul, Rahem
Pharmaceutical Journal of Indonesia Vol. 10 No. 2 (2025)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Bronchopneumonia is an infectious disease in toddlers that produces high mortality, morbidity, and costs. The research aims to investigate the cost-effectiveness of ampicillin and cefuroxime for treating bronchopneumonia in toddlers. Data was collected retrospectively from medical records and hospital information systems between March 2023 and August 2023. The hospital-based trial was completed in October 2023. Stratified random sampling was employed to gather samples from those who met the inclusion criteria, which included using ampicillin or cefuroxime and having bronchopneumonia symptoms. Therapeutic success was determined by achieving a normal breathing rate within < 3 days, taking into account total direct medical expenses. The study discovered that the average direct medical cost for ampicillin patients is Rp. 2,792,875 ± 454.704, and for cefuroxime patients, Rp. 2.931.682 ± 908.964 per inpatient. The effectiveness of antibiotics showed that ampicillin (98%) surpassed cefuroxime (96%). Ampicillin's average cost-effectiveness ratio (ACER) is Rp. 28,499, which is less than cefuroxime's Rp. 30,538. The findings of calculating the incremental cost-effectiveness ratio (ICER) of ampicillin and cefuroxime are Rp. -69,404. Ampicillin has lower direct medical costs and higher effectiveness than cefuroxime, making it a more cost-effective therapy for bronchopneumonia in toddlers. Cost-effectiveness pharmacoeconomic studies are necessary to analyze therapy options
Cost-Effectiveness Analysis of The Antibiotic Ampicillin and Cefuroxime for Bronchopneumonia Patients Toddlers at Secondary Hospital in Surabaya Wardhani, Dewanti; Firdaus, Favian Rafif; Yunita, Nita; Abdul, Rahem
Pharmaceutical Journal of Indonesia Vol. 10 No. 2 (2025)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Bronchopneumonia is an infectious disease in toddlers that produces high mortality, morbidity, and costs. The research aims to investigate the cost-effectiveness of ampicillin and cefuroxime for treating bronchopneumonia in toddlers. Data was collected retrospectively from medical records and hospital information systems between March 2023 and August 2023. The hospital-based trial was completed in October 2023. Stratified random sampling was employed to gather samples from those who met the inclusion criteria, which included using ampicillin or cefuroxime and having bronchopneumonia symptoms. Therapeutic success was determined by achieving a normal breathing rate within < 3 days, taking into account total direct medical expenses. The study discovered that the average direct medical cost for ampicillin patients is Rp. 2,792,875 ± 454.704, and for cefuroxime patients, Rp. 2.931.682 ± 908.964 per inpatient. The effectiveness of antibiotics showed that ampicillin (98%) surpassed cefuroxime (96%). Ampicillin's average cost-effectiveness ratio (ACER) is Rp. 28,499, which is less than cefuroxime's Rp. 30,538. The findings of calculating the incremental cost-effectiveness ratio (ICER) of ampicillin and cefuroxime are Rp. -69,404. Ampicillin has lower direct medical costs and higher effectiveness than cefuroxime, making it a more cost-effective therapy for bronchopneumonia in toddlers. Cost-effectiveness pharmacoeconomic studies are necessary to analyze therapy options